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Abstract The antimicrobial effect of taurolidine was tested
against periodontopathic species in comparison to chlo-
rhexidine digluconate in the presence or absence of serum.
Minimal inhibitory concentrations (MIC), microbiocidal
concentrations (MBC), as well as killing were determined
against 32 different microbial strains including 3 Porphyr-
omonas gingivalis, 3 Aggregatibacter actinomycetemcomi-
tans, and 15 potentially superinfecting species with and
without 25% v/v human serum. The MIC50 of taurolidine
against the tested microbial strains was 0.025% and the
MIC90 0.05%. The respective values for the MBCs were
0.05% and 0.1%. Addition of 25% serum (heat-inactivated)
did not change the MIC and MBC values of taurolidine. In
contrast, MICs and MBCs of chlorhexidine (CHX)
increased by two steps after addition of serum. Taurolidine
killed microorganisms in a concentration and time-
dependent manner, the killing rate of 1.6% taurolidine
was 99.08%±2.27% in mean after 2 h. Again, killing
activity of taurolidine was not affected if serum was added,
whereas addition of inactivated serum clearly reduced the
killing rate of all selected bacterial strains by CHX.
Therefore, taurolidine possesses antimicrobial properties
which are not reduced in the presence of serum as a main
component in gingival crevicular fluid and wound fluid.
Taurolidine may have potential as an antimicrobial agent in
non-surgical and surgical periodontal treatment.
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Taurolidine is a derivative of the amino acid taurine.
Taurine is not incorporated into proteins. It plays a role in
the development of the central nervous system, the retina
membrane stabilization, and immune response. The level of
the enzyme cysteine sulfinic acid decarboxylase which is
required for biosynthesis of taurine is low in humans.
Therefore, the intake of taurine occurs via food, i.e., it is
found especially in seafood and meat [1]. Decreased plasma
levels of taurine have been reported in trauma and sepsis
[2]. Taurolidine acts as an antibacterial agent and prevents
adhesion of bacteria to epithelial cells [3]. Taurolidine
inhibits production of proinflammatory cytokines, such as
interleukin (IL)-1 and tumor necrosis factor (TNF)-α [4].
Animal studies with cats fed a taurine-free diet resulted in a
significant reduction of phagocytosis rate of Staphylococ-
cus epidermidis [5]. Hamsters treated with supplementary
taurine did not develop typical oxidant tissue damage after
NO2 exposure [6]. Taurine reacts with HOCl and produces
the less reactive and more stable taurine chloramines [1].
The activity of taurolidine is not influenced by organic
matter such as blood [7]. The systemic toxicity of
taurolidine appears to be low indicated by the finding that
healthy volunteers were administered 5 g of taurolidine per
day without serious adverse effects [8]. In vitro, toxic
effects were observed after 30 min exposure of 0.5%
taurolidine to chondrocytes but still being less in compar-
ison to 3% hydrogen peroxide and 0.04% polyhexanide [9].
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Taurolidine is used in the prevention of catheter-related
infections [10] and in bone infections [11]. A possible
application is discussed in the treatment of tumors since it
has been shown that taurolidine promotes apoptosis of
tumor cells [12].
Due to its properties, taurolidine may be also a promising
disinfectant in the therapy of periodontitis and peri-
implantitis. However, at present, chlorhexidine (CHX)
represents the gold standard among the disinfectants used
for the treatment of periodontal and peri-implant infections.
Chlorhexidine is active against many microbial species [13–
15], but it may exert some cytotoxic effect as shown in some
in vitro studies [16, 17]. Furthermore, the antimicrobial
activity of chlorhexidine is strongly reduced in the presence
of serum [18], which in turn, limits its effectiveness in the
subgingival environment. Therefore, there is a stringent need
to search for novel agents exhibiting an antimicrobial activity
in the presence of serum or blood thus having a potential for
clinical application in the subgingival environment. Al-
though taurolidine may represent a potential agent against
periodontopathic bacteria, the available data are still very
limited. Therefore, the aim of this in vitro study was to
evaluate the antimicrobial effect of taurolidine against
selected periodontopathic species in comparison to chlorhex-
idine digluconate in the presence or absence of serum.
Materials and methods
Antimicrobials
Taurolidine was available as a 2% solution, which,
according to the manufacturer's information, was the high-
est concentration to be solubilized (Geistlich Pharma AG,
Wolhusen, Switzerland), while 0.1% chlorhexidine digluc-
onate (CHX) solution (B. Braun, Melsungen, Germany)
was used as a positive control. Different dilutions with
dH2O were made from these concentrations. Sodium
chloride (0.9%) served as the negative control.
Microorganisms
In total, 32 different microbial strains were included in the
study. Seventeen of these strains belonged to species clearly
involved in pathogenesis of periodontitis (“real” periodon-
topathogens); the 15 others may play a role as potentially
superinfecting species. Among them, 11 bacterial strains
were Gram-positive, 20 Gram-negative, and 1 strain was a
yeast. Beside laboratory strains, clinical isolates were
included. Three P. gingivalis strains, three A. actino-
mycetemcomitans strains, as well as six potentially super-
infecting species, originated from clinical samples obtained
from patients with severe periodontitis (Table 1).
All the strains were precultivated 24–72 h prior to the
experiments. Modified tryptic soy agar [19] (“real” perio-
dontopathic bacteria) and trypic soy agar were used as
cultivation media. A. actinomycetemcomitans strains and
Streptococcus constellatus ATCC 27823 were always
incubated with 5% CO2, the other “real” periodontopath-
ogens were incubated anaerobically and all potentially
superinfecting species within normal atmospheric condi-
tions, each at 37°C.
Minimal inhibitory and minimal microbiocidal
concentrations
Micro-broth dilution technique was used to determine
minimal inhibitory concentrations (MICs). After subculti-
vation of bacterial strains (and a yeast species) and
checking of purity, a defined inoculum was added to a
broth containing defined concentrations of the antimicro-
bials. The range of the tested final concentrations were
0.0004–0.025% for chlorhexidine digluconate and
0.00625–0.4% for taurolidine. Mueller-Hinton broth was
used for the superinfecting species and Wilkins-Chalgren
broth added by 2.5 mg l−1 vitamin K, 5 mg l−1 hemin,
10 mg l−1 N-acetylmuramic-acid, and 5% blood was the
medium used for the others. After an incubation time of
42 h (18 h aerobes), the growth of microbes was analyzed
by visual checking of turbidity. The MIC represented the
lowest concentration without visible turbidity. MIC50 and
MIC90 data are the values for MICs where 50% and 90% of
the strains were inhibited in their growth. In case of
Wilkins-Chalgren broth with all the additives, it was
difficult to register visually turbidity. Here, subcultivation
of all wells was made, and MIC was defined as the
concentration showing clearly less growth than the control.
For determination of minimal microbiocidal (mostly bacte-
ricidal) concentration (MBC), non-turbid cultures were
subcultivated on agar plates without the addition of any
antimicrobial agent. After incubation, MBCs were mea-
sured as the lowest concentration without any colonies on
agar plates. MBC50 and MBC90 represent the concentra-
tions where 50% and 90% of the strains were completely
killed.
Determination of MICs and MBCs were repeated in the
presence of 25% v/v inactivated human serum (Sigma-
Aldrich, Steinheim, Germany). Serum had been inactivated
by heating to 56°C for 30 min to determine exclusively the
inhibitory effect of serum proteins and to exclude a killing
by the complement cascade as a component of the serum.
Native serum (without inactivation) was additionally used
for six selected species to consider the possible bactericidal
effect of complement in addition to the serum proteins. The
following bacterial strains were included in these experi-
ments: A. actinomycetemcomitans J7, Fusobacterium
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nucleatum ATCC 25586, P. gingivalis ATCC 33277, S.
constellatus ATCC 27823, Enterobacter cloacae JGr1, and
Staphylococcus aureus MRSA VA25607/2.
Killing activity
A defined inoculum of microorganisms (about 104) in 0.9%
w/v NaCl with 0.01% (w/v) yeast extract was added by
taurolidine and CHX in different concentrations (CHX—
0.005%, 0.02%, 0.008%; taurolidine—0.1%, 0.4%, 1.6%).
After 1 and 2 h of incubation, the numbers of viable
bacteria were determined by enumeration of colony form-
ing units. Determination of killing rates was repeated for six
species in the presence of 25% v/v inactivated and native
serum. The same bacterial strains which were included in
the MIC and MBC experiments with native serum were
tested. Here, the lowest concentration of each antimicrobial
was chosen, only P. gingivalis ATCC 33277 was tested in
the presence of 0.4% taurolidine; without serum, 0.1%
taurolidine did not show any killing effect.
All experiments were made in independent duplicate.
Methods were adapted to the guidelines of Clinical and
Laboratory Standards Institute [20, 21].
Scanning electron microscopy photographs
Four strains (F. nucleatum ATCC 25586, P. gingivalis
ATCC 33277, A. actinomycetemcomitans J7, S. aureus
Species Origin Gram
“Real” periodontopathic
Fusobacterium nucleatum ATCC 25586 Laboratory strain Negative
Prevotella intermedia ATCC 25611 Laboratory strain Negative
Porphyromonas gingivalis ATCC 33277 Laboratory strain Negative
P. gingivalis M5-1-2 Clinical isolate Negative
P. gingivalis MaRL Clinical isolate Negative
P. gingivalis J430-1 Clinical isolate Negative
Tannerella forsythia ATCC 43037 Laboratory strain Negative
Aggregatibacter actinomycetemcomitans ATCC 33384 Laboratory strain Negative
A. actinomycetemcomitans J1 Clinical isolate Negative
A. actinomycetemcomitans J2 Clinical isolate Negative
A. actinomycetemcomitans J7 Clinical isolate Negative
Campylobacter rectus ATCC 33238 Laboratory strain Negative
Eikenella corrodens ATCC 23834 Laboratory strain Negative
Capnocytophaga gingivalis ATCC 33624 Laboratory strain Negative
Eubacterium nodatum ATCC 33099 Laboratory strain Positive
Parvimonas micra ATCC 33270 Laboratory strain Positive
Streptococcus constellatus ATCC 27823 Laboratory strain Positive
Potentially superinfecting species
Enterobacter cloacae JGr1 Clinical isolate Negative
Klebsiella pneumonia JGr2 Clinical isolate Negative
Pseudomonas aeruginosa DSM 50071 Laboratory strain Negative
Escherichia coli VA25304/2-09 (ESBL) Clinical isolate Negative
E. coli VA25488/1-09 (ESBL) Clinical isolate Negative
E. coli BK 20303-09 (ESBL) Clinical isolate Negative
Enterococcus faecalis ATCC 29212 Laboratory strain Positive
Staphylococcus aureus ATCC 29213 Laboratory strain Positive
S. aureus ATCC 43300 (MRSA) Laboratory strain Positive
S. aureus MR8126-09 (MRSA) Laboratory strain Positive
S. aureus VA25607/2-09 (MRSA) Clinical isolate Positive
Enterococcus faecium VA23477/1-09 Clinical isolate Positive
E. faecium UR17400-09 Clinical isolate Positive
E. faecium ST10343-09 Clinical isolate Positive
Candida albicans ATCC 76615 Laboratory strain Yeast
Table 1 Tested microorganisms
and their characteristics (origin,
Gram characteristics)
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VA25607/2-09) were chosen for scanning electron micros-
copy (SEM) photographs. An overnight culture was placed
on slides and exposed to aqueous solutions containing
0.08% CHX and 1.6% taurolidine solutions and dH2O
(control) for 1 h at 37°C. After removal of the solution, the
bacteria were carefully washed with dH2O and initially
fixed in 2% glutaraldehyde in cacodylate buffer for 30 min,
washed twice with cacodylate buffer and dehydrated using
a graded ethanol series (10 min each concentration).
Following critical point drying, samples were sputtercoated
with gold and examined with a ZEISS LEO-1530 Gemini
(Carl Zeiss NTS GmbH, Oberkochen, Germany) equipped
with a field emission electron gun at 10 keV.
Results
Determination of minimal inhibitory and minimal
microbiocidal concentrations with and without serum
The MIC50 of CHX against the tested microbial strains was
0.0008% and the MIC90 0.0016%. The respective values
for MBC50 and MBC90 were 0.0008% and 0.0063%.
Addition of 25% serum (heat-inactivated) enhanced the
MIC and MBC values by up to three steps. The MIC50 and
MIC90 with serum were 0.0063% and 0.0125%. The
MBC50 and MBC90 values were 0.0125% and 0.025%.
The MIC50 of taurolidine against the tested microbial
strains was 0.025% and the MIC90 0.05%. The respective
values for the microbiocidal concentrations were 0.05% and
0.1%. Addition of 25% serum (heat-inactivated) did not
enhance the MIC and MBC values in general. The MIC50
and MIC90, as well as the MBC50 with serum, were the
same as without. Only the MBC90 value was one step
higher and reached 0.2% (Fig. 1).
Additionally, the effect of native (non-inactivated) serum
was tested on six selected species. In mean, MIC of CHX
increased by two steps after addition of non-activated
serum. Using native serum resulted in the same MICs for
four strains, unexpectedly, a higher MIC was registered for
S. constellatus ATCC 27823 compared to inactivated
serum. MBCs of CHX increased at least by two steps after
addition of non-activated serum. Using native serum
resulted in the same MBCs for three strains, lower MBCs
Fig. 1 Cumulative minimal inhibitory concentration (MIC) and
minimal bactericidal concentrations (MBC) of chlorhexidine digluco-
nate and taurolidine against all tested strains (n=32) with and without
serum. MICs and MBCs were determined by using micro-broth
dilution technique. Serum was added in a final concentration of 25%
v/v after being inactivated to exclude a potential bactericidal effect of
complement
Table 2 Minimal inhibitory concentrations of chlorhexidine digliuconate against selected species without, as well as with inactive and native
serum
Strain MIC/MBC of chlorhexidine without serum with inactivated serum with native serum
A. actinomycetemcomitans J7 0.0016/0.0016 0.0063/0.0063 0.0063/0.0063
F. nucleatum ATCC 25586 ≤0.0004/≤0.0004 0.0031/0.0031 0.0031/0.0031
P. gingivalis ATCC 33277 ≤0.0004/≤0.0004 0.0008/0.0016 0.0016/0.0016
S. constellatus ATCC 27823 0.0004/0.0004 0.0016/0.0031 0.0250/0.0500
E. cloacae JGr1 0.0063/0.0063 0.0250/0.1000 0.0250/0.0250
S. aureus MRSAVA25607/2 0.0016/0.0031 0.0063/0.0125 0.0063/0.0063
Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by using micro-broth dilution
technique. Serum was added in a final concentration of 25% v/v native and after being inactivated to exclude a potential bactericidal effect of
complement
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were registered for the two involved potentially super-
infecting species and S. constellatus ATCC 27823 was less
susceptible compared to inactivated serum (Table 2). The
MICs of taurolidine did not increase after addition of
inactivated serum, contrary S. aureus MRSA VA25607/2
was slightly more susceptible. Using native serum resulted
in the same MICs for four strains, the MICs of two other
strains changed only slightly by one step (one MIC was
higher, the other lower). In general, MBCs of taurolidine
did not change after addition of inactivated serum; only the
MBC of S. aureus MRSA VA25607/2 was one step higher
than without. Using native serum resulted in the same
MBCs for two strains, lower MBCs were registered for the
two involved potentially superinfecting species as well as
for P. gingivalis ATCC 33277, and only S. constellatus
ATCC 27823 was slightly less susceptible compared to the
inactivated serum (Table 3).
Killing
CHX was highly efficient in killing the tested micro-
organisms. In mean, the killing rate was more than 99% for
all three tested concentrations after 2 h. For taurolidine, a
concentration and time-dependent effect was visible. Nev-
ertheless, the killing rate of the highest tested concentration
of 1.6% was 99.08%±2.27% after 2 h (Fig. 2.). All
concentrations of CHX and the highest tested concentration
of taurolidine (1.6%) completely erradicated most of the
strains after 2 h. Here, taurolidine eliminated all Gram-
negative potentially superinfecting strains (Table 4). Addi-
tion of inactivated serum clearly reduced the killing rate of
all selected bacterial strains by CHX; moreover, F.
nucleatum ATCC 25586 was obviously stimulated to
multiply. Compared to the inactivated serum, native serum
increased the killing rates of all species. Serum did not
influence clearly the killing ability of taurolidine, except for
E. cloacae JGR1, where it was reduced (Fig. 3).
SEM photographs
Three Gram-negative and one Gram-positive species were
chosen for electron microscopy. Gram-negative bacteria
having an outer membrane seemed to be more damaged by
the antimicrobials. After exposure to chlorhexidine, a flow
out of substances is clearly visible. In part, bacteria seemed
to have burst. The damages were not as obvious after
exposure to taurolidine. The surface appeared to be rough;
impressions suggest also a flow out of inner particles, but to
a much less extent, compared to chlorhexidine. The surface
of S. aureus VA25607-02/09 (MRSA) appeared unchanged
after exposure of the antimicrobials. An outer membrane is
missing in Gram-positives, and the inner membrane is
covered by a thick peptidoglycan layer. Thus, possible
damages to the inner membrane might not be visible
(Fig. 4).
Discussion
The antimicrobial activity of taurolidine has been known
for more than 20 years. It was first used in the prevention
and treatment of peritonitis [22]. In the present study, we
compared taurolidine with chlorhexidine digluconate which
Table 3 Minimal inhibitory concentrations of taurolidine against selected species without, as well as with inactive and native serum
Strain MIC/MBC of taurolidine without serum with inactivated serum with native serum
A. actinomycetemcomitans J7 0.0125/0.0125 0.0125/0.0125 <=0.0063/0.0125
F. nucleatum ATCC 25586 0.0125/0.0125 0.0125/0.0125 0.0125/0.0125
P. gingivalis ATCC 33277 0.0125/0.0250 0.0125/0.0250 0.0125/0.0125
S. constellatus ATCC 27823 ≤0.0063/0.0063 ≤0.0063/0.0063 0.0125/0.0125
E. cloacae JGr1 0.0500/0.1000 0.0500/0.1000 0.0500/0.0500
S. aureus MRSAVA25607/2 0.0500/0.0500 0.0250/0.1000 0.0250/0.0250
Fig. 2 Changes in viabilities of microorganisms by different
chlorhexidine digluconate and taurolidine concentrations after 1 and
2 h. Reduction of viability is shown. That means, −100% represents a
complete elimination. Changes of viability was calculated for each
strain separetely; the mean and standard deviation for all 32
investigated strains are presented
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is one of the best documented antimicrobial agents in
dentistry [23]. The MICs of taurolidine were all below 5%
of the normally used concentration of that substance with
the exception of Candida albicans ATCC 76615. This
confirms the findings from an earlier study which deter-
mined MIC values against seven oral species; among them,
one F. nucleatum and one Prevotella intermedia strain [24].
Similar to this study [24], lower MIC values were found for
chlorhexidine compared to taurolidine.
With the exception of the C. albicans strain which was
found being completely resistant to taurolidine, minimal
microbiocidal concentrations of that antimicrobial were in
mean one to two steps higher than the MICs. Additionally
to C. albicans, taurolidine showed only a limited bacteri-
Microbial strains (number) CHX (%) Tauroline (%)
0.005 0.02 0.08 0.1 0.4 1.6
“Real” periodontopathogens
Gram-positive bacteria (3) 1 2 3 0 1 1
Gram-negative bacteria (14) 11 14 14 1 6 11
Potentially superinfecting
Gram-positive bacteria (9) 4 9 9 0 4 8
Gram-negative bacteria (5) 2 4 4 0 0 5
Candida albicans (1) 1 1 1 0 0 0
Table 4 Number of strains
which were totally killed after
addition of the antimicrobials
for 2 h
Microorganisms (104 ) were
added by taurolidine and CHX in
different. After 2 h of incubation,
the numbers of viable bacteria
were determined by enumeration
of colony forming units. The
number of strains which were
totally killed is listed (detection
level, ten microorganisms)
Fig. 3 Influence of serum
(inactivated and native) on
killing rates of selected bacterial
strains by 0.005% chlorhexidine
digluconate and 0.1% (P.
gingivalis 0.4%) taurolidine
after 1 h. Concentrations of the
disinfectants have been chosen
in relation to the MIC values.
Serum was added in a final
concentration of 25% v/v.
Comparison of native with
inactivated serum shows the
potential bactericidal effect of
complement. Changes of viabil-
ity are shown, negative values
mean killing efficacy of the
compounds, whereas positive
values suggest a growth-
promoting effect
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cidal effect on E. faecalis ATCC 29213, which is known as
the test strain for antiseptics; the MBC for that species was
0.4% being 40% of the normal concentration. Thus, the
present results confirm earlier MIC and MBC values
reported for taurolidine, even a larger difference between
MIC and MBC values for E. faecalis [25].
Focusing on the included species, different aspects need
to be pointed out. First of all, taurolidine was more active
against the “real” periodontopathogens compared to the
potentially superinfecting species. This might be attributed
to the more or less incomplete activity against the included
C. albicans strain. Secondly, taurolidine was found to be
similarly active against Gram-positive and Gram-negative
bacterial strains. This is in accordance with an earlier study
where aerobic and anaerobic species originated from
dentoalveolar infections were tested [26]. Taurolidine is
described as an unstable molecule in aqueous solution,
while masked formaldehyde is released which inactivates
endotoxin [27]. Furthermore, it was suggested that other
mechanisms such as interaction with peptidoglycan con-
tribute to the antimicrobial action [28]. SEM photographs
of Gram-negative species appear to support an interaction
with compounds of the cell wall.
In the MIC assays, the chosen highest test concentrations
being in the range of about 20% of the concentrations in
commercially available products were selected because of
the necessity to add nutrient broth and bacterial suspension.
This reflects also a general rule in pharmacology for
Fig. 4 Fusobacterium nucleatum ATCC 25586, Porphyromonas
gingivalis ATCC 33277, Aggregatibacter actinomycetemcomitans J7,
and Staphylococcus aureus (MRSA) VA25607-02/09 (from top to
bottom) after 1 h exposure of 0.08% chlorhexidine (middle) and 1.6%
taurolidine (right) as well as a control (left)
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antibiotics that MICs should exceed the in vitro concentra-
tion by the factors 2 to 8 [29]. In the killing assays, up to
80% of the application concentration was tested. At that
concentration, both taurolidine and chlorhexidine reduced the
viability of the microorganisms by more than 99% after 2 h in
general. Most of the used microbial strains were completely
killed. But taurolidine exerted a clear concentration and time-
dependent effect. Killing was enhanced after 2 h. At a lower
concentration of taurolidine, the antimicrobial activity was
often completely blocked. Based on the findings, it may be
anticipated that a sufficient high concentration of taurolidine
needs to be ensured for several hours, while a dilution of
taurolidine, e.g., by the flow of gingival crevicular fluid
should be avoided as much as possible. Thus, from a clinical
point of view, the choice of an optimal carrier device, ensuring
a long-lasting, sufficiently high concentration of the active
substance, appears to be a key factor, which may significantly
affect the therapeutic use. In the treatment of periodontal
infections, the topical application of antibiotics incorporated
in various types of controlled released devices, i.e., such as
gels [30, 31] or microspheres [32] represents an important
therapeutic modality.
Gingival crevicular fluid contains up to 35% of the
albumin found in serum [33]. After non-surgical and
surgical periodontal treatment, serum-rich wound fluid is
produced. Therefore, the activity of antimicrobials in the
presence of serum plays an important role. Our results
clearly indicate that taurolidine was active in a serum-rich
environment, while on the contrary, the efficacy of
chlorhexidine was dramatically decreased. This finding
may suggest that taurolidine may be also applied in a
serum-rich environment, e.g., after periodontal surgery. An
enhanced bactericidal activity of taurolidine in the presence
of serum as described before [34] was not always found.
This might be associated with a resistance of many
periodontopathogens against killing by complement [35,
36]. In killing assays, both the potential inhibiting effect of
serum proteins and the complement activity are combined
with the efficacy of the antimicrobials. In the present study,
only selected strains were tested, and it can be suggested
that the complement effect does not overcome an inhibition
by the other serum compounds.
Serum may also be an important component of subgin-
gival plaque being a biofilm. The special conditions of
biofilms were not addressed in this study. An earlier made
study found a plaque-growth reducing effect of taurolidine
which was less pronounced in comparison to chlorhexidine
[37]. Recently, experiments in healthy volunteers have
shown a decreased viability in supragingival plaque after
2 min of rinsing with taurolidine; again, the potential
antimicrobial effect was not as high as after rinsing with
chlorhexidine [38]. In that study, the bactericidal effect was
determined immediately after the 2-min exposure. Con-
cluding from our results showing a time-dependent antimi-
crobial effect of taurolidine at a later time-point differences
might be less remarkable between the two antimicrobials. A
depot effect can be suggested for taurolidine, as a lock
solution, prevents successful infections in catheters [39].
Biofilms are organized microbial communities surrounded
by a biopolymer matrix and characterized by slow growth,
increasing mutation frequency, and maximum tolerance to
antibiotics [40]; the special conditions of biofilms should be
addressed in subsequent studies testing taurolidine.
Pathogenesis of periodontitis comprises the microbial
challenge and the host response with an inflammatory and
immune response directed to cope with the challenge. The
host response results in production of many proinflamma-
tory cytokines involved in inflammation and bone loss
[41]. It is well-established that periodontopathic bacteria
are able to attach and to invade epithelial cells [42, 43],
while polymorphonuclear neutrophils interacting with
periodontopathic bacteria release reactive oxidative spe-
cies [44], which in turn damage the soft and hard
periodontal tissues. Taurolidine has been demonstrated to
inhibit adhesion of Escherichia coli, Staphylococcus
saprophyticus, and C. albicans to mucosal epithelial cells
[3] and of Gram-negative species to plastic surfaces [39].
Taurolidine derivatives decrease production of proinflam-
matory cytokines and oxidants [45]. Thus, the positive
immunomodulatory properties of taurolidine might be of
importance in periodontitis and should be analyzed in
further in vitro and in vivo studies.
Taken together, the present findings suggest that: (a)
taurolidine possesses antimicrobial properties which are not
reduced in the presence of serum which is a main
component in gingival crevicular and wound fluid and (b)
the demonstrated in vitro antimicrobial properties of
taurolidine warrant further evaluation in non-surgical and
surgical periodontal therapy.
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